vs
Side-by-side financial comparison of Andersons, Inc. (ANDE) and Bio-Techne (TECH). Click either name above to swap in a different company.
Andersons, Inc. is the larger business by last-quarter revenue ($329.5M vs $295.9M, roughly 1.1× Bio-Techne). Andersons, Inc. runs the higher net margin — 20.5% vs 12.8%, a 7.6% gap on every dollar of revenue. On growth, Andersons, Inc. posted the faster year-over-year revenue change (-2.4% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs -1.8%).
The Andersons, Inc. is an American agribusiness established in 1947, that began as Andersons Truck Terminal (ATT) in the 1940s for the grain industry, headquartered in Maumee, Ohio. It is a diversified company rooted in agriculture that conducts business in the commodity merchandising, renewables, and plant nutrient sectors.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
ANDE vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $329.5M | $295.9M |
| Net Profit | $67.4M | $38.0M |
| Gross Margin | 70.3% | 64.6% |
| Operating Margin | 26.6% | 18.4% |
| Net Margin | 20.5% | 12.8% |
| Revenue YoY | -2.4% | -6.4% |
| Net Profit YoY | 49.6% | 68.3% |
| EPS (diluted) | — | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $329.5M | $295.9M | ||
| Q3 25 | $295.8M | — | ||
| Q2 25 | $535.0M | $317.0M | ||
| Q1 25 | $370.8M | $316.2M | ||
| Q4 24 | $337.5M | $297.0M | ||
| Q3 24 | $231.9M | $289.5M | ||
| Q2 24 | $492.5M | $306.1M | ||
| Q1 24 | $341.4M | $303.4M |
| Q4 25 | $67.4M | $38.0M | ||
| Q3 25 | $20.1M | — | ||
| Q2 25 | $7.9M | $-17.7M | ||
| Q1 25 | $284.0K | $22.6M | ||
| Q4 24 | $45.1M | $34.9M | ||
| Q3 24 | $27.4M | $33.6M | ||
| Q2 24 | $36.0M | $40.6M | ||
| Q1 24 | $5.6M | $49.1M |
| Q4 25 | 70.3% | 64.6% | ||
| Q3 25 | 57.8% | — | ||
| Q2 25 | 29.6% | 62.7% | ||
| Q1 25 | 41.2% | 67.9% | ||
| Q4 24 | 63.1% | 65.3% | ||
| Q3 24 | 76.4% | 63.2% | ||
| Q2 24 | 35.6% | 66.4% | ||
| Q1 24 | 37.6% | 67.4% |
| Q4 25 | 26.6% | 18.4% | ||
| Q3 25 | 8.7% | — | ||
| Q2 25 | 4.6% | -7.5% | ||
| Q1 25 | 0.9% | 12.2% | ||
| Q4 24 | 19.9% | 16.0% | ||
| Q3 24 | 26.8% | 13.8% | ||
| Q2 24 | 11.6% | 15.0% | ||
| Q1 24 | 4.1% | 22.1% |
| Q4 25 | 20.5% | 12.8% | ||
| Q3 25 | 6.8% | — | ||
| Q2 25 | 1.5% | -5.6% | ||
| Q1 25 | 0.1% | 7.1% | ||
| Q4 24 | 13.4% | 11.7% | ||
| Q3 24 | 11.8% | 11.6% | ||
| Q2 24 | 7.3% | 13.3% | ||
| Q1 24 | 1.6% | 16.2% |
| Q4 25 | — | $0.24 | ||
| Q3 25 | $0.59 | — | ||
| Q2 25 | $0.23 | $-0.11 | ||
| Q1 25 | $0.01 | $0.14 | ||
| Q4 24 | $1.31 | $0.22 | ||
| Q3 24 | $0.80 | $0.21 | ||
| Q2 24 | $1.05 | $0.26 | ||
| Q1 24 | $0.16 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $98.3M | $172.9M |
| Total DebtLower is stronger | $560.0M | $260.0M |
| Stockholders' EquityBook value | $1.2B | $2.0B |
| Total Assets | $3.7B | $2.5B |
| Debt / EquityLower = less leverage | 0.45× | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $98.3M | $172.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | $561.8M | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | — | $152.9M | ||
| Q1 24 | — | $145.3M |
| Q4 25 | $560.0M | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | $608.2M | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $1.2B | $2.0B | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.4B | $1.9B | ||
| Q1 25 | $1.4B | $2.0B | ||
| Q4 24 | $1.4B | $2.1B | ||
| Q3 24 | $1.3B | $2.1B | ||
| Q2 24 | $1.3B | $2.1B | ||
| Q1 24 | $1.3B | $2.0B |
| Q4 25 | $3.7B | $2.5B | ||
| Q3 25 | $3.3B | — | ||
| Q2 25 | $3.4B | $2.6B | ||
| Q1 25 | $3.8B | $2.6B | ||
| Q4 24 | $4.1B | $2.7B | ||
| Q3 24 | $3.4B | $2.7B | ||
| Q2 24 | $3.3B | $2.7B | ||
| Q1 24 | $3.3B | $2.7B |
| Q4 25 | 0.45× | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | 0.45× | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.2M | — |
| Free Cash FlowOCF − Capex | $-77.1M | — |
| FCF MarginFCF / Revenue | -23.4% | — |
| Capex IntensityCapex / Revenue | 21.5% | — |
| Cash ConversionOCF / Net Profit | -0.09× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-56.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.2M | — | ||
| Q3 25 | $233.9M | — | ||
| Q2 25 | $299.3M | $98.2M | ||
| Q1 25 | $-350.0M | $41.1M | ||
| Q4 24 | $268.8M | $84.3M | ||
| Q3 24 | $-2.1M | $63.9M | ||
| Q2 24 | $304.4M | $75.5M | ||
| Q1 24 | $-239.6M | $81.0M |
| Q4 25 | $-77.1M | — | ||
| Q3 25 | $167.0M | — | ||
| Q2 25 | $250.5M | $93.3M | ||
| Q1 25 | $-396.6M | $31.0M | ||
| Q4 24 | $212.9M | $77.5M | ||
| Q3 24 | $-40.0M | $54.7M | ||
| Q2 24 | $275.8M | $57.5M | ||
| Q1 24 | $-266.4M | $64.5M |
| Q4 25 | -23.4% | — | ||
| Q3 25 | 56.5% | — | ||
| Q2 25 | 46.8% | 29.4% | ||
| Q1 25 | -106.9% | 9.8% | ||
| Q4 24 | 63.1% | 26.1% | ||
| Q3 24 | -17.2% | 18.9% | ||
| Q2 24 | 56.0% | 18.8% | ||
| Q1 24 | -78.0% | 21.3% |
| Q4 25 | 21.5% | — | ||
| Q3 25 | 22.6% | — | ||
| Q2 25 | 9.1% | 1.5% | ||
| Q1 25 | 12.6% | 3.2% | ||
| Q4 24 | 16.6% | 2.3% | ||
| Q3 24 | 16.3% | 3.2% | ||
| Q2 24 | 5.8% | 5.9% | ||
| Q1 24 | 7.8% | 5.4% |
| Q4 25 | -0.09× | — | ||
| Q3 25 | 11.61× | — | ||
| Q2 25 | 38.10× | — | ||
| Q1 25 | -1232.46× | 1.82× | ||
| Q4 24 | 5.96× | 2.42× | ||
| Q3 24 | -0.08× | 1.90× | ||
| Q2 24 | 8.46× | 1.86× | ||
| Q1 24 | -42.94× | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANDE
| Specialty And Primary Nutrients | $137.1M | 42% |
| Premium Ingredients | $66.1M | 20% |
| Segment Reporting Reconciling Item Other | $63.2M | 19% |
| Other | $63.1M | 19% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
